ElevateBio BaseCamp Unveils its LentiPeakTM Lentiviral Vector Platform-biotech.vision

ElevateBio BaseCamp Unveils its LentiPeakTM Lentiviral Vector Platform

The patented LentiPeakTM lentiviral vector platform developed by ElevateBio BaseCamp, a technology-driven firm focused on enabling transformational cell and gene treatments have been made public. Regulatory-compliant therapeutically relevant vector yields have been produced with great volumetric productivity using the serum-free, suspension-based LentiPeak production platform. Leveraging ElevateBio BaseCamp’s end-to-end process and analytical development expertise, scientific leadership, and current Good Manufacturing Practice (cGMP) manufacturing capabilities for research, clinical, and commercialization, LentiPeak will enable efficient transition for cell and gene therapies from the preclinical stage through clinical development and commercialization with accelerated timelines and lower manufacturing costs.

“As a 30-year veteran of the cell and gene therapy industry, I’ve witnessed the immense advancement of lentiviral vector technology from its infancy to the current landscape with six FDA-approved lentiviral vector-derived cell and gene therapies, The LentiPeak platform is made possible by ElevateBio’s strong scientific foundation, industry-leading expertise, and the investments we’ve made into viral vector production. Our pioneering work continues to be the basis for our continued innovation to drive many more therapies through development to commercialization for our partners.”

-Mitchell Finer, Ph.D., Co-founder and President of R&D, ElevateBio

The LentiPeak platform from ElevateBio BaseCamp provides a reliable and expandable platform method for the creation and cGMP manufacture of lentiviral vectors. The LentiPeak platform makes use of a serum-free suspension approach that can generate clinically relevant lentiviral vectors with high titers of between 1×108 and 1×109 TU/ml, suited for a range of therapeutic program demands from the preclinical stage to commercial scale supply. ElevateBio’s capacity to carry out both vector and cell manufacturing activities enables the LentiPeak platform to be effortlessly incorporated into cell therapy initiatives. The LentiPeak platform will streamline the product development and commercialization lifecycle by utilizing the aligned process unit operations, materials, analytics, and manufacturing expertise at ElevateBio BaseCamp. This will reduce complexity and guarantee comparability between early-stage and pivotal trials.

“Our team of industry-leading experts has developed next-generation platform-based processes that are designed to address lentivirus manufacturing challenges head-on. With our partners’ needs in mind, our proprietary LentiPeak platform has demonstrated leading vector titers with high potency, and process scalability to help our partners de-risk vector production, right from the start, At ElevateBio BaseCamp, we are ever committed to simplifying the complex cell and gene therapy landscape to enable our partners to rapidly progress their therapeutic programs and make these therapies more accessible to patients in need.”

-Andrew Sandford, President, ElevateBio BaseCamp

About ElevateBio:

ElevateBio is a technology-driven business created to support the creation of revolutionary cell and gene treatments both now and in the foreseeable future. In order to promote innovation and the commercialization of cellular and genetic medicines, the company has gathered industry-leading talent, constructed cutting-edge facilities, and integrated a variety of technology platforms, including gene editing, induced pluripotent stem cells (iPSCs), protein, vector, and cellular engineering. A facility specifically designed to offer process innovation, process sciences, and current Good Production Practice (cGMP) manufacturing capabilities is ElevateBio BaseCamp in Waltham, Massachusetts. It was created to support a range of cell and gene therapy products, including those made using autologous, allogeneic, and regenerative medicine cells as well as the production of viral vectors.

ElevateBio is focused on expanding its partnerships with business partners while also creating its own portfolio of cellular and genetic therapies using BaseCamp and its enabling technologies. The border between technology and healthcare is being blurred by ElevateBio’s team of scientists, drug researchers, and business creators as they redefine what it means to be a technology firm in the realm of drug development.

Leave a Reply

Your email address will not be published. Required fields are marked *